tiprankstipranks
Advertisement
Advertisement
Innoviva reports Q4 EPS $1.94 vs. 26c last year
PremiumThe FlyInnoviva reports Q4 EPS $1.94 vs. 26c last year
2M ago
Innoviva initiated with a Buy at BTIG
Premium
The Fly
Innoviva initiated with a Buy at BTIG
3M ago
Innoviva: Durable Royalty Backbone and High-Growth Hospital Portfolio Underpin Buy Rating and $35 Target
Premium
Ratings
Innoviva: Durable Royalty Backbone and High-Growth Hospital Portfolio Underpin Buy Rating and $35 Target
3M ago
Roth Capital healthcare analyst holds an analyst/industry conference call
PremiumThe FlyRoth Capital healthcare analyst holds an analyst/industry conference call
5M ago
Innoviva Reports Strong Q3 2025 Financial Results
Premium
Company Announcements
Innoviva Reports Strong Q3 2025 Financial Results
6M ago
Innoviva management to meet virtually with Oppenheimer
Premium
The Fly
Innoviva management to meet virtually with Oppenheimer
6M ago
Innoviva’s Future Challenges: Sell Rating Amid Patent Cliff and Revenue Pressures
PremiumRatingsInnoviva’s Future Challenges: Sell Rating Amid Patent Cliff and Revenue Pressures
7M ago
Innoviva initiated with a Sell at Goldman Sachs
Premium
The Fly
Innoviva initiated with a Sell at Goldman Sachs
7M ago
Arm initiated, Adobe downgraded: Wall Street’s top analyst calls
Premium
The Fly
Arm initiated, Adobe downgraded: Wall Street’s top analyst calls
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100